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Muscle spindles are an essential part of the neuro-muscular system because they act as 
sensory receptors of muscle and limb position that communicate with the nervous system and 
sense movement. It has been established that the neuregulin1(NRG1}- ErbB signaling pathway 
plays a key role in the formation of muscle spindles. Our research aims to further characterize 
this pathway and more specifically the role of the transcription factor serum response factor 
(SRF), which previous evidence suggests may be a downstream effector during NRG 1 signaling. 
To address how SRF is targeted during neuregulin signaling, we have generated muscle cells that 
inactivate endogenous SRF and express a truncated mutant form of SRF, using retroviral 
transduction and CRISPR/Cas9. These cells were then stimulated with NRGl and qRT-PCR was 
used to measure expression of Early growth response 3 (Egr3), which is a key target gene 
activated by SRF in the NRG1-ErbB pathway. In these cells, transcription ofEgr3 is induced by 
NRG 1 consistent with wild-type cells. These results suggest that transcriptional induction of 
Egr3 by NRG1 occurs independently ofthe N-and C- terminal domains ofSRF and the MADS 
box is sufficient for induction. Future experiments will further investigate the MADS box and its 
interactions with known co factors in the development of muscle spindles. 
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Process Analysis 
Diseases which target muscles and their nerve connections are not completely understood, 
which is reflected in the number of therapeutics available for them. According to Center of Disease 
Control statistics, hundreds of young males aged 5 - 24 are diagnosed with muscular dystrophy 
every year. Sensory neuropathies caused by infection, inheritable disease, trauma, or diabetes are 
estimated to affect 20 million people in the United States alone. While symptoms can be managed, 
there are currently no cures for muscular dystrophy or sensory neuropathies. Serum response factor 
(SRF) is a protein which has been shown to play a role in the formation of muscle spindles, which 
are muscle fibers innervated with nerves. In this study, we focus on how SRF is targeted in a 
specific pathway which is essential for muscle spindle development. Previous studies have shown 
promise for using SRF as a therapeutic target in disease, and studying how it functions in muscle 
spindle development gets us closer to applying this knowledge to treatment of muscular disorders 
and sensory neuropathies. 
The MADS box of serum response factor is sufficient for induction of muscle spindle-
specifying gene Egr3 by neuregulin is a significant study which has created a useful biotechnology 
tool in the form of a cell line expressing mutated forms of our protein of interest, SRF. During this 
project, I utilized many molecular biology techniques including recombinant DNA creation, 
polymerase chain reaction (PCR), cell culture techniques, and protein isolation and analysis to 
work towards our goal of assessing the function of SRF in a muscle spindle development pathway. 
CRISPR/Cas9 is an emerging genome editing technology which comprised a major premise of my 
experiments. This work is novel because the function of different domains of SRF in this pathway 
have not been previously characterized. 
This work has not only prepared me for a career in research, but it has contributed to ~he 
Fromm laboratory and the scientific community. The outcome of this project, a mutant cell line, 
will benefit the Fromm laboratory in possible future experiments where the role of SRF in muscle 
spindle formation will be investigated further. In addition, we have demonstrated efficiency of an 
experimental approach for genome editing using CRISPR and isolating cells which express a 
particular genotype. The goal of our research was to learn more about how SRF functions in muscle 
spindle .development and our results benefit the scientific community by providing insight on the 
molecular interactions that occur in the induction of muscle spindles. In the future, SRF may be a 
novel therapeutic target in diseases of muscular disorders and sensory neuropathies. 
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Introduction 
Muscle spindles are an essential part of the neuro-muscular system because they act as 
sensory receptors of muscle and limb position that communicate with the nervous system via 
afferent nerve fibers and sense movement. Spindles consist of specialized muscle fibers, known 
as intrafusal muscle fibers and axons of the sensory neurons that innervate them (1). Muscle 
fibers require inductive cell signaling interactions with sensory axons to become intrafusal 
muscle fibers (2). The neuregulin-1 (NRG 1 )-ErbB pathway is a cell signaling pathway known to 
induce specification of intrafusal muscle fibers. In this pathway, NRG 1 is a signaling protein 
released by sensory axons, which then activates its receptors, known as ErbEs, in muscle cells 
that are contacted. Early growth response 3 (Egr3) is an essential protein in this pathway which 
acts downstream of ErbEs and functions as a transcription factor that activates the target genes 
that form intrafusal muscle fibers . Egr3 has been shown to be activated by NRG 1-ErbB signaling 
at the level of its own transcription through transcription factors serum response factor (SRF) and 
cAMP response element binding (CREE) (3). 
Current understanding of how SRF is activated by signaling pathways is that it occurs 
through two families of signal-regulated coactivators, myocardin-related transcription factors 
(MRTFs) and ternary complex factors (TCFs). These coactivators are known to interact with a 
domain within SRF known as the MADS box, which also functions as the DNA binding domain 
( 4, 5). SRF recognizes and binds to specific recognition elements in regulatory regions of 
particular genes, and in conjunction with its interacting coactivators, induces the transcription of 
these target genes. Previous evidence suggests that SRF may be regulated by other means not 
involving MRTFs or TCFs in the NRG 1-ErbB pathway in muscle cells (6). These other 
mechanisms potentially could be through SRF phosphorylation or through its interaction with 
other coactivators. 
To study the function ofSRF, the sequence can be divided into three general domains: an 
N-terminal region, a central DNA binding region (MADS box), and a C-terminal region. Both 
theN-terminal region and the C-terminal region are not well-characterized, but features such as 
phosphorylation sites suggest they could function in SRF activation. The C-terminal region has 
been shown to exhibit transcriptional activation function in transcriptional reporter assays in 
transfected cells (7, 8). In this study, both the C-terminal and N-terminal domains ofSRF were 
deleted in cultured muscle cells to assess the role of these domains of SRF in NRG 1 signaling, 
and more specifically transcriptional induction of Egr3 (Figure 2). 
The experimental system being used in the current studies utilizes C2C12 cells, which is 
an established muscle cell line originating from mouse skeletal muscles that are used to study 
muscle developmental processes. These cells can be propagated as myoblasts and differentiated 
to form multinucleate myotubes. C2C12 cells have been used in previous experiments studying 
the NRG 1-ErbB pathway (3, 6). The C2C 12 cell culture system we are using involves 
stimulating the cells with soluble NRG 1, which will start the NRG 1-ErbB signaling cascade 
when NRG 1 binds to ErbB receptors. Because Egr3 acts downstream of SRF, assessing Egr3 
level will be used to analyze transcriptional response in the pathway and determine whether 
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mutant SRF affects signaling. We hope that stimulation ofC2Cl2 myotubes with NRG1 models 
signaling from afferent nerve fibers in developing intrafusal muscle fibers. 
In the current studies, DNA coding for SRF amino acids 88-265 was placed in a retroviral 
plasmid vector using PCR and DNA cloning. The resulting SRF-88-265-expressing retrovirus 
was transduced into C2C12 muscle cells, and endogenous SRF was subsequently inactivated 
using CRISPR/Cas9 in a pool of cells. Single cell cloning was used to isolate cells which had a 
homozygous frameshift mutation in endogenous SRF, which completely inactivated its function. 
The cells were differentiated in culture media and stimulated with NRG 1. Real-time PCR 
( qPCR) was used to determine transcriptional activation by comparing Egr3 levels in NRG 1:.. 
stimulated and unstimulated cells. 
Studying SRF and its function in NRG 1 signaling is important in public health because 
understanding how muscle spindles are innervated can provide useful therapeutic targets in 
diseases where nerves and their connections are destroyed, such as sensory neuropathies, and 
muscular disorders. SRF has shown promise in being a therapeutic target (9), and investigating 
its role in NRG 1 signaling may premise a novel therapeutic for these diseases, where there are 
currently limited options for effective treatments. 
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Methods 
Creation of recombinant DNA 
A plasmid containing human SRF (pCGN-SRF) (8) was linearized with BamHl. 
Linearized pCGN-SRF was added to PCR containing PrimeSTAR GXL DNA polymerase 
(Takara R050A). The forward primer contained a BamHI site, coding sequences for an HA 
epitope tag, and a portion of the SRF gene beginning at amino acid 88. The reverse primer 
contained a portion of the SRF gene ending at amino acid 265, followed by a stop codon and an 
Xhol site. PCR conditions were as follows : initial denaturation at 98°C for 5 minutes (98°C for 
10 seconds, 55°C for 15 seconds, 68°C for 50 seconds X 28 cycles). PCR sample was purified 
with a gel extraction kit (Sigma NA1111) and restriction digested with BamH1 and Xho. 
Digested PCR fragment containing and HA tag and SRF amino acids 88-265 was isolated by gel 
extraction. The fragment was ligated into BamHI-Xhol digested pENTR11 (Invitrogen) using T4 
DNA ligase. This ligation was then transformed into DH5a bacteria and selected on kanamycin 
plates. Plasmid DNA from bacteria was isolated using Mini-Prep kit (Sigma PLN70) and 
confirmed by BamHI-Xhol digestion and DNA sequencing. SRF 88-265 was then transferred 
from pENTR11 to pQXIB using LR clonase. 
Cell culture 
C2C12 myoblasts were propagated using growth media (Dulbecco's Modified Eagle 
Medium (DMEM) (Coming Scientific 15-013-CM), 20% bovine growth serum (GE Healthcare 
Life Sciences SH30541), 4mM glutamine, 50 ug/ml Gentamycin (Gibco 15750-060)). 
Differentiation to myotubes was induced by propagating cells to confluence and replacing media 
with differentiation media (DMEM, 4% horse serum (GE Healthcare Life Sciences SH30074), 
4mM glutamine, 50 ug/ml Gentamycin) was added. Cells were incubated at 37°C and 10% C02. 
Retroviral transduction 
pQXIB SRF 88-265 was transfected into Bosc23 retroviral packaging line cells (10) 
using Lipofectamine. Bosc23 cells were seeded at 2.2 X 106 cells/35mm plate using DMEM, 
10% bovine growth serum, 4mM glutamine, 50 ug/ml Gentamycin. The next day, media was 
removed and 3.3 ug of DNA and 6.6 uL Lipofectamine (Invitrogen 11668) were diluted in 500 
uL Opti-MEM Reduced Serum Media (Gibco 31985070) and added to cells. Cells were 
propagated for two days. The media, which contained retroviral particles, was harvested and 2 
ml was added to C2C12 myoblasts, seeded the day before at 6 x 104 cells on a 35 mm dish. 
8ug/ml polybrene was also added to the cells. Transduced C2C 12 cells were propagated and 
stably transduced cells were selected using Blasticidin (Invitrogen) treatment (8 ug/ml) for 4-6 
days. The cells were then subjected to adenoviral transduction. 
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Adenoviral transduction 
C2C12 cells that had been stably transduced with SRF 88-265 were seeded at 6 x 104 
cells per 35mm plate. The next day, recombinant adenovirus containing guide RNA targeting 
nucleotide 228 of endogenous SRF and recombinant adenovirus containing Cas9 were added to 
the cells. Cells were propagated for one week in media containing blasticidin, splitting cells as 
needed to avoid crowding. Cells reached confluency and growth media was replaced with 
differentiation media. Cells were re-fed with differentiation media 2 days after. 2 days after the 
re-feeding, a cell lysate was made using RIP A lysis buffer and protease inhibitors. 
Dilution cloning 
A 96-well plate was prepared by adding 100 uL of growth media to each well. 1 X 103 of 
retroviral/adenoviral transduced cells in 100 uL was placed into well Al. Two-fold serial 
dilutions were performed down column 1 and then 100 uL of growth media was placed in each 
well of column 1, giving a final volume of200 uL. Two-fold serial dilutions were performed 
across all rows, starting with column 1. WT C2Cl2 were diluted to 2.5 X 103 cells/ml in 14 ml of 
suspension. 100 uL of this suspension was added to each well of the 96-well plate to help 
transduced mutant SRF cells grow. Cells were propagated for two days and then treated with 
Blasticidin (8 ug/ml) to kill WT cells. Selection continued for three days. Wells in which clonal 
populations appear to have risen from a single cell were isolated and expanded to larger plates 
gradually. These clones were differentiated and lysates were harvested for analysis. 
SDS-PAGE/Western blot 
Celllysates were prepared using RIPA lysis buffer (50 mM Tris- HCl, (pH 8.0), 150mM 
NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 0.4mM EDTA) with 1% protease 
inhibitor cocktail (Sigma P8340). Lysates were treated with SDS sample buffer (200 mM Tris-
HCl, pH6.8, 400 mM DTT, 8% SDS, 0.4% Bromophenol Blue, 40% glycerol) and incubated at 
95°C to induce denaturation. Samples were run on a 10% polyacrylamide gel and transferred to a 
PVDF membrane (GE Healthcare Life Sciences 10600029) using the Hoefer Semi-Dry Transfer 
apparatus. The membrane was blocked with 5% milk in TBST (137 mM Sodium Chloride, 20 
mM Tris-HCl, pH 7.6, 0.1% Tween-20) for an hour to prevent nonspecific binding of antibody. 
The blot was incubated in either 1:1000 dilution of SRF primary antibody (Cell Signaling 
Technology D71A9) or HA-tag primary antibody (Cell Signaling Technology C29F4) in 
blocking buffer overnight. The membrane was incubated in 1:2000 dilution of anti-rabbit IgG 
secondary antibody (Cell Signaling Technology 7074) for an hour and subjected to peroxidase 
chemo-luminescence reagents (Thermo fisher Scientific 1859698 & 1859701) before imaging 
with the Kodak Image Station 4000. 
qPCR 
Differentiated myotubes in 35mm dishes were serum-starved for two hours by replacing 
differentiation media with DMEM. Plates were either treated with neuregulinl (HRGpl, R&D 
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Systems, 100 ng/ml) or left untreated for approximately 2 hours. RNA was extracted using RNA 
STAT-60 (Tel-Test CS502). Reverse transcriptase (RT) PCR using Affinity-Script eDNA 
Synthesis Kit (Stratagene 200436) created complementary DNA (eDNA) from 3 ug extracted 
RNA and random primers. eDNA was used in real-time (qPCR) using Brilliant SYBR Green 
QPCR Kit (Stratagene 600828) with Egr3 primers GCCCATTACAATCAGATGGCT (forward), 
GCTCGAATAAGAGAGTTCCGGA (reverse) or with GABPa primers to normalize expression. 
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Results and Discussion 
The functions of the N- and C-terminal domains of SRF are unknown, but features such 
as phosphorylation sites and transcriptional activation function suggest that these domains could 
be involved in activation of SRF in the NRG 1-ErbB pathway. If these domains are required for 
the signaling cascade, it would suggest that SRF functions independent of known signaling-
regulated cofactors. To study the effect ofthe N-and C-terminal domains ofSRF, a mutant form 
lacking these domains (containing amino acids 88-265) was introduced into C2C12 muscle cells 
and the endogenous form of SRF was inactivated using CRISPR/Cas9. These cells were then 
stimulated with NRG 1 to assess the efficiency of the NRG 1-ErbB pathway in cells lacking the 
N-and C-terminal domains ofSRF. Level ofEgr3 expression is indicative ofthe transcriptional 
response to NRG 1 that occurs through SRF because Egr3 transcription in response to NRG 1 
requires SRF (3) (Figure 1). 
TheN- and C-terminal domains were studied by deleting the coding sequences within 
SRF and assessing the effects. SRF 88-265 was created by removing theN- and C- termini of 
SRF using PCR-based mutagenesis (Figure 2). Using retroviral transduction, SRF 88-265 was 
transduced into C2C12 myoblasts. C2C12 cells expressing SRF 88-265 were subjected to 
CRISPR, in which adenoviral transduction was used to introduce guide RNA (gRNA) and Cas9 
to target endogenous SRF for inactivation. Because the gRNA targets a sequence in theN-
terminus, SRF 88-265 was not affected by CRISPR. SRF expression was analyzed by Western 
blot analysis. Expression of endogenous SRF was reduced in a pool of cells using CRISPR/Cas9 
(Figure 3). Wild-type C2C12, which contain only normal SRF (508 amino acids), cells 
transduced with SRF amino acids 88-508, and cells transduced with SRF 88-265 that had not 
been subject to CRISPR/Cas9 were controls, which show similar expression level of endogenous 
SRF. SRF 88-265 transduced with CRISPR/Cas9 shows a lower expression for endogenous SRF, 
indicating that endogenous SRF is partially inactivated. 
The gRNA was designed to target the SRF gene to be cut by Cas9. After Cas9 cuts at the 
targeted site within the SRF gene, non-homologous end joining repairs the DNA at the double 
strand break. This type of repair typically creates short deletions or occasionally insertions (11, 
12) Ideally, the repair would result in a frameshift mutation, disrupting the translation of SRF 
downstream of the gRNA target sequence. Because we targeted SRF in theN-terminus, a 
frame shift mutation would result in no translation of the MADS box and the C-terminal domain, 
which would completely inactivate the function of endogenous SRF. However, sometimes the 
DNA repair results in small in-frame deletions due to randomness of non-homologous end 
joining. In this case, endogenous SRF with a small internal deletion would be generated and 
might still be functional. The cell pool created presumably contains some cells that are still 
expressing endogenous SRF with small in-frame deletions, some which are heterozygous for a 
frameshift mutation, and some which are a homozygous for a frameshift mutation. A 
homozygous frameshift mutation would completely inactivate endogenous SRF, allowing us to 
assess the effect of SRF 88-265 on NRG 1 signaling without interference of endogenous SRF. 
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To isolate cell clones from this pool which contained a homozygous frameshift mutation 
of endogenous SRF, dilution cloning was used. Multiple clonal populations originating from a 
single cell were isolated and genotypes were assessed using Western blot. Clonal population G2 
shows no expression for endogenous SRF, indicating homozygous inactivation of the 
endogenous SRF gene, while expressing mutant SRF 88-265 (Figure 4). Seven other clonal 
populations that were analyzed show varying expression levels of endogenous SRF. Not all 
clonal populations contained cells which could fuse, which is likely due to the procedure of 
dilution cloning, which can cause cellular stress and can isolate cells that favor fibroblastic 
instead of myoblastic characteristics. 
In clone G2, endogenous SRF expression was replaced with mutant SRF 88-265, which 
lacked theN- and C-terminal domains. These cells were propagated to confluence and switched 
to differentiation media, inducing myotube differentiation. It is known that SRF is essential for 
muscle cell differentiation, which is the formation of elongated, multinucleate myotubes from 
myoblasts (13). Clone G2 was able to form myotubes even though it lacked theN- and C-
terminal domains of SRF (Figure 5), which suggests that only the MADS box (amino acids 88-
265) is necessary for myotube differentiation. Myogenesis and muscle spindle development 
presumably occur via different signaling pathways, so although theN- and C-terminal domains 
of SRF is not necessary for myotube formation, it could still have a role in transcriptional 
activation in NRG 1 signaling. 
To assess transcriptional activation within the NRG1-ErbB pathway, myotubes from 
clone G2 were treated with NRG1 (Figure 1). Stimulating with NRG1 models NRG1 input from 
sensory axons in vivo. The extent of Egr3 transcription in response to NRG 1 was evaluated using 
real-time qPCR with a NRGl treated and an untreated control. We found that Egr3 expression, 
both basal expression and transcriptional induction by NRGl, was consistent among wild-type 
C2C12 cells with full-length SRF and mutant C2C12 cells with truncated SRF 88-265 (Figure 
6). This suggests that theN- and C-terminal domains do not function in transcriptional activation 
of Egr3 in NRG 1 signaling, and therefore only the MADS box, which mediates DNA binding 
and interaction with known signal-regulated coactivators, functions in the pathway. Levels of 
Egr3 in both control and mutant cells were higher in samples treated with NRG 1 than in 
untreated, which aligns with results seen in Herndon et al (6). 
In these experiments, a C2C12 muscle cell line expressing truncated SRF 88-265 was 
created to assess ifthe N-and C-terminal domains ofSRF function in the NRG1-ErbB pathway 
to transcriptionally activate Egr3, an essential protein for muscle spindle development. We found 
that theN- and C-terminal domains do not function in transcriptional activation ofEgr3, which 
suggests that within SRF, the MADS box, which mediates DNA binding and interaction with 
known signal-regulated coactivators, is sufficient for NRG 1 signaling. The limitations of our 
study include not having more control samples for examining Egr3 expression, such a mutant 
SRF with only N-terminus deleted, having only a single mutant cell line for analysis, and lack of 
repeat experimental trials. In addition, cultured C2Cl2 cells may not behave consistently with in 
vivo cells after NRG 1 stimulation. Future experiments include further investigating the MADS 
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box to study if it can function within the NRG 1 pathway independent of known signal-regulated 
coactivators MRTFs and TCFs. SRF is known to be required for induction of the muscle-spindle 
gene Egr3 by NRG 1 (3). Studying how SRF is activated has implications for medicine which 
include possible ways to target SRF activation for therapeutic use in diseases such as muscular 
disorders and sensory neuropathies. SRF has shown promise for being a therapeutic target in 
disease (9). By targeting SRF activation, effectors of the NRG 1-ErbB pathway could be 
upregulated to increase the transcription of muscle spindle-specific genes, promoting formation 
of muscle fibers of muscle spindles. This would be a novel therapeutic for muscular diseases and 
sensory neuropathies, where there are currently limited options for effective treatments. 
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Figure 1. Model for the NRGl-ErbB signaling pathway that induces formation of muscle · 
spindles. SRF has been shown to be a component of this pathway. Experiments here address 
how SRF might be targeted as part of the signaling response. Figure was modified from Dr. 
Larry Fromm. 
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N-terminal domain 
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HA tag 
SRF 88-265 
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Figure 2. Mutant SRF 88-265 lacks N- and C-terminus. The truncated form of SRF was 
created by amplifying the nucleotides corresponding to amino acids 88-265 in PCR. Amino acids 
88-265 include the DNA binding domain. An HA-tag was added N-terminal to amino acid 88 
and allows for detection of mutant SRF via Western blot. 
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Figure 3. Generation of a pool of C2C12 cells that express truncated SRF 88-265 and that 
partially inactivate endogenous SRF. C2C12 cells were generated by retroviral transduction to 
express exogenous truncated forms of SRF that contain an HA epitope tag. Endogenous SRF was 
partially inactivated with CRISPR, in which SRF gRNA targeting the SRF gene corresponding to 
amino acid 76 and Cas9 were introduced by adenoviral transduction. Expression of endogenous 
SRF was assayed by Western blot using an antibody to SRF that recognizes an epitope that is C-
terminal to amino acid 265. Residual endogenous SRF expression presumably reflects not all 
gRNA targeting events resulting in frameshift mutations. Blot was reprobed with HA antibody, 
which demonstrated expression of exogenous SRF (not shown, see figure 2B). Equal loading 
was confirmed by Coomassie staining. 
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Figure 4. Clonal population G2 has no expression of endogenous SRF while expressing 
truncated SRF 88-265. C2C12 cell populations from SRF 88-265/CRISPR/Cas9 pool were 
isolated using dilution cloning and assayed by Western blot. Expression of endogenous SRF was 
visualized by probing blot with SRF antibody that detects an epitope C-terminal of amino acid 
265 (A). Sample G2 shows no expression of endogenous SRF, which suggests that all cells in the 
sample have a homozygous frameshift mutation in both alleles for the gene. Sample SRF 88-265 
is a positive control showing full expression of endogenous SRF. Expression of truncated SRF 
88-265 was visualized by re-probing blot with an antibody that recognizes the HA-tag present in 
the protein (B). Equal loading was confirmed using Coomassie staining (not shown) . 
• 
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C2C12 G2 
Figure 5. C2C12 cells lacking the N- and C-terminal domains of SRF are able to form 
myotubes. Endogenous SRF was completely inactivated in clonal population G2 using CRISPR. 
G2 expresses truncated SRF with amino acids 88-265 (see figure 4). Lack ofN- and C-terminal 
SRF did not affect the cell's ability to form myotubes, which are differentiated, multi-nucleate 
fibers. 
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Figure 6. Egr3 expression in response to NRG 1 was consistent among wild-type C2C12 and 
C2C12 with SRF 88-265. RNA was extracted from differentiated myotubes that had been 
stimulated with NRG 1 or left untreated and subjected to reverse transcription. Complementary 
DNA was analyzed by real-time PCR using primers for Egr3. GABPa expression, which is not 
affected by NRGl, was used to normalize Egr3 expression values. Wild-type C2C12 cells 
express full-length SRF while SRF 88-265 express the mutant truncated form lacking N-and C-
terminus. 
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